Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from scPharmaceuticals ( (SCPH) ).
On September 23, 2025, scPharmaceuticals Inc. issued an unsecured promissory note to MannKind Corporation in exchange for a $10 million loan. This financial move is part of a larger merger agreement with MannKind Corporation, which involves a tender offer to acquire all outstanding shares of scPharmaceuticals. The promissory note includes specific terms regarding maturity and interest rates, and it reflects the ongoing strategic efforts of scPharmaceuticals to align with MannKind, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SCPH) stock is a Hold with a $5.35 price target. To see the full list of analyst forecasts on scPharmaceuticals stock, see the SCPH Stock Forecast page.
Spark’s Take on SCPH Stock
According to Spark, TipRanks’ AI Analyst, SCPH is a Neutral.
scPharmaceuticals’ overall stock score is primarily impacted by its financial instability, with high debt levels and negative cash flows posing significant risks. However, strong technical indicators and positive strategic developments, such as the merger with MannKind Corporation, provide a counterbalance, suggesting potential for future growth. The earnings call further supports optimism with robust revenue growth and strategic advancements, despite ongoing cost challenges.
To see Spark’s full report on SCPH stock, click here.
More about scPharmaceuticals
scPharmaceuticals Inc. is a Delaware corporation operating in the pharmaceutical industry. The company focuses on developing and commercializing products for the treatment of heart failure and other medical conditions.
Average Trading Volume: 1,074,578
Technical Sentiment Signal: Buy
Current Market Cap: $302.2M
For a thorough assessment of SCPH stock, go to TipRanks’ Stock Analysis page.